The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Asparaginase Completion Rate
Timeframe: Assessed at the end of the 30-week post-induction treatment period or when the participant comes off treatment, whichever occurs first.